Press Releases
Eisai Receives Complete Response Letter from FDA for Rabeprazole...
Eisai announced that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA)...
Press Releases
15 Merck & Co senior executives join the eyeforpharma...
15 senior directors registered for eyeforpharma’s SFE 2011 (29-31 March, Dusseldorf) meeting. The Event Director Kate Eversole stated, “I am overwhelmed by the amount of...
Press Releases
Protagen at the Personalized Medicine and Diagnostics Europe Congress...
Protagen AG, a specialist for GMP-compliant protein analysis and in-vitro diagnostics is presenting at the Personalized Medicine and Diagnostics Europe Congress in London. Dr. Stefan...
Press Releases
PIA Vietnam to return in March 2011 with broader...
The next edition of PIA Vietnam, a premier trade event focused on process engineering and instrumentation as well as laboratory and scientific equipment, will be...
Press Releases
Allan Mackintosh, PMAP Performance Coach, Grunenthal, on the evolving...
Allan Mackintosh, PMAP Performance Coach, Gruenthal believes that the KAM approach is where we will see most change within the pharma industry over the next...
Press Releases
Roche personalized investigational medicine shows survival benefit in advanced...
Roche announced that BRIM3, a Phase III clinical study of RG7204 (PLX4032), met its co-primary endpoints showing a significant survival benefit in people with previously...
Press Releases
ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved...
ARIAD Pharmaceuticals, Inc. announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.